Business UpdateMay 20, 2026, 08:33 AM
Ernexa Highlights ERNA-101 Potential in Ovarian Cancer via KOL Segment
AI Summary
Ernexa Therapeutics announced a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, a Yale Professor and Ernexa Board member. Dr. Ratner discussed the significant unmet need in ovarian cancer and the limitations of current therapies. The segment highlighted Ernexa's lead product candidate, ERNA-101, and its preclinical data showing complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade. The discussion also covered the advantages of Ernexa's scalable, off-the-shelf allogeneic iMSC platform.
Key Highlights
- Ernexa released a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner.
- Dr. Ratner, a Yale Professor and Ernexa Board member, discussed ovarian cancer.
- Segment highlighted significant unmet need and limitations of current ovarian cancer therapies.
- ERNA-101 preclinical data showed complete tumor elimination in ovarian cancer models.
- Preclinical data also demonstrated 100% long-term survival in ovarian cancer models.
- Discussion covered Ernexa's engineered allogeneic iMSC platform advantages.
- Platform offers scalable, off-the-shelf cell therapies to improve accessibility.
Price Impact
More from ERNA